Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Kuros Biosciences ( (CH:KURN) ) has provided an announcement.
Kuros Biosciences announced changes to its Board of Directors, with Albert Arp resigning and Oliver Walker and Kimberley Elting taking on new roles within the board. These changes could impact the company’s governance and strategic direction, potentially influencing its market position and stakeholder relations.
The most recent analyst rating on (CH:KURN) stock is a Hold with a CHF28.00 price target. To see the full list of analyst forecasts on Kuros Biosciences stock, see the CH:KURN Stock Forecast page.
More about Kuros Biosciences
Kuros Biosciences is a company focused on discovering, developing, and delivering innovative biologic technologies. With operations in the United States, Switzerland, and the Netherlands, Kuros is listed on the SIX Swiss Exchange. The company’s flagship product, MagnetOs, is an advanced bone graft used globally, offering surgeons predictable fusion outcomes without the risk of disease transmission.
Average Trading Volume: 251,632
Technical Sentiment Signal: Buy
Current Market Cap: CHF917.1M
For detailed information about KURN stock, go to TipRanks’ Stock Analysis page.